Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial
Background Many patients with type 2 diabetes do not achieve sustained diabetes remission after metabolic (bariatric) surgery for the treatment of obesity. Liraglutide, a glucagon-like peptide-1 analogue, improves glycaemic control and reduces bodyweight in patients with type 2 diabetes. Our aim was to assess the safety and efficacy of liraglutide 1·8 mg in patients with persistent or recurrent type 2 diabetes after metabolic surgery. Methods In the GRAVITAS randomised double-blind, placebo-controlled trial, we enrolled adults who had undergone Roux-en-Y gastric bypass or vertical sleeve gastr... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Journal article |
Erscheinungsdatum: | 2019 |
Verlag/Hrsg.: |
Elsevier BV
|
Schlagwörter: | Science & Technology / Life Sciences & Biomedicine / Endocrinology & Metabolism / Y GASTRIC BYPASS / DUTCH EATING BEHAVIOR / BARIATRIC SURGERY / WEIGHT-LOSS / SLEEVE GASTRECTOMY / GUT HORMONES / FOOD-INTAKE / REMISSION / QUESTIONNAIRE / EXPENDITURE / Aged / Diabetes Mellitus / Type 2 / Double-Blind Method / Female / Humans / Hypoglycemic Agents / Liraglutide / Male / Middle Aged / Postoperative Complications / 1101 Medical Biochemistry and Metabolomics / 1103 Clinical Sciences / 1117 Public Health and Health Services |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26634109 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/10044/1/85812 |